Page 13 - Dr Reddy’s Laboratories
Dr Reddy's strong drug pipeline comes to the fore
Dr Reddy's was the biggest gainer among the Sensex stocks as brokerage upgrades as well as US FDA approval for one of its plants saw the stock move up nearly 7.5 per cent. The easing regulatory pressures and plant approvals helps the company launch new products and capitalise on niche opportunities. This is the second unit that has received the establishment inspection report after Miryalaguda (Telengana) got the green signal from the US FDA in February this year. The receding plant related worries means that the street will now turn to the company's product portfolio and launch timeline to gauge the revenue potential in the US market. Deepak Malik of Edelweiss Securities believes that a large and increasing complex generics pipeline in the US, tripling of biosimilar revenues to $150 million over the FY18-20 period will lead to a 53 per cent growth in the company's net profit over the same period. Analysts believe that a strong product pipeline (including niche opportunities) should .
 "Dr Reddy's strong drug pipeline comes to the fore")
Dr Reddy's shares jump 7.5%; m-cap rises by Rs 2,864 cr
On NSE, shares of the company soared 7.42% to close at Rs 2,486.55
Dr Reddy's Labs gains as Srikakulam SEZ Unit II get EIR from USFDA
The stock moved higher by nearly 7% to Rs 2,466 on BSE in an otherwise weak market
 "Dr Reddy's Labs gains as Srikakulam SEZ Unit II get EIR from USFDA")
US FDA makes 3 observations after inspecting Dr Reddy's UK plant
Form 483 issued to the firm's management over violation of regulatory norms
Dr Reddy's falls as firm gets 6 observations in Duvvada facility audit
The stock dipped 7% to Rs 2,066 on NSE in intra-day trade
Dr Reddy's falls 9% in two days on disappointing Q1 results
The stock dipped 6% to Rs 2,470, extending its previous day's 3% decline on BSE
 "Dr Reddy's falls 9% in two days on disappointing Q1 results")
Dr Reddy's out licenses phase-3 clinical trial drug to CHD Biosciences
The drug candidate is used for the prevention of surgical site infections
 "Dr Reddy's out licenses phase-3 clinical trial drug to CHD Biosciences")
USFDA observations 'unmistakably' beneficial in long run: Dr Reddy's
Dr Reddy's adds that these observations helped the company to accelerate pace of quality reforms
 "USFDA observations 'unmistakably' beneficial in long run: Dr Reddy's")
Dr Reddy's announces commercialisation of Vozet tablets in India
Vozet tablets are used for the treatment of allergic Rhinitis and chronic Urticaria
 "Dr Reddy's announces commercialisation of Vozet tablets in India")
Dr Reddy's gains on receiving EIR for Miryalaguda plant
The stock was up 3% to Rs 2,698 on BSE in intra-day trade.
Dr Reddy's SEZ unit completes USFDA inspection for second time
US drug regulator audited company's API manufacturing unit at the same plant in April
 "Dr Reddy's SEZ unit completes USFDA inspection for second time")
Dr Reddy's biosimilars capacity gets boost with GE Healthcare's FlexFactory
BS ReporterHyderabad, 19 MayDr Reddy's Laboratories (DRL) will install India's first single-use manufacturing platform to expand the biologics production capacity at its facility in Hyderabad. GE Healthcare's bio-manufacturing platform FlexFactory will help the Hyderabad-based drug major increase its capacity to meet both the expected growth of its currently marketed biosimilars as well as support the launch of new biosimilar products in the next few years. With this, the pharma company will boost its manufacturing capacity as the overall project set-up timeline for FlexFactory is typically 9 to 12 months. It will continue to grow patient access globally for biotech-based therapies.The new FlexFactory enables DRL's transition from stainless steel to single-use technologies that bring enhanced flexibility and efficiency into their manufacturing set-up. Single-use technologies facilitate multi-product manufacturing and improve productivity by increasing the number of lots manufactured. .
Dr Reddy's Q4 net profit rises 3-fold to Rs 337.6 cr
Shares of the company were trading 0.14% down at Rs 2,588.75 on BSE
Dr Reddy's hits 52-week low ahead of Q4 results
Since Feb 3, post Q3FY17 results, the stock declined 19% as compared to 7% rise in Sensex.
Dr Reddy's gains as USFDA completes inspection of Srikakulam SEZ unit
The stock was up 3% at Rs 2,712 against 0.18% decline in the S&P BSE Sensex at 09:30 am.
Dr Reddy's Srikakulam unit receives Form 483 with 2 observations
Srikakulam unit is among three facilities that received warning letter from US FDA in Nov 2015
Dr Reddy's unit fails to clear US FDA audit
The US drugs regulator had issued a warning letter to three of firm manufacturing facilities
No claims for monetary damages: Dr Reddy's on patent infringement
Claims sought injunctive relief to prohibit manufacturing, use, import, sale of palonosetron product prior to expiration
 "No claims for monetary damages: Dr Reddy's on patent infringement")
Dr Reddy's hits 52-week low on patent infringement
The stock hit a 52-week low of Rs 2,799, down 4% on the National Stock Exchange in intra-day trade.
Dr Reddy's launches generic drugs in France, to expand operations in Europe
The company recently launched select products of its hospital portfolio in Italy and Spain